By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ProNAi Therapeutics, Inc. 

4717 Campus Drive
Suite 1100
Kalamazoo  Michigan  49008  U.S.A.
Phone: 269-372-3289 Fax: 269-544-1079


ProNAi Therapeutics is a drug development company focused on advancing targeted therapeutics for the treatment of patients with cancer. We are an ambitious oncology drug development company oriented towards registration and commercialization. We have a world-class management team with a proven track record of success in oncology drug development and we intend to build a broad and diverse pipeline of promising oncology assets against emerging targets on the leading edge of cancer biology.




CEO: Nick Glover

CFO: Sukhi Jagpal

CSO (Scientific): Angie You


Please click here for ProNAi job opportunities.

FOLLOW ProNAi Therapeutics

Key Statistics

Ownership: Private

Web Site: ProNAi Therapeutics

Company News
ProNAi Therapeutics Reports Third Quarter 2016 Results 11/11/2016 1:34:25 PM
ProNAi Therapeutics To Present At The 15th Annual BIO Investor Forum In San Francisco 10/13/2016 8:52:52 AM
ProNAi Therapeutics Strikes a $328.5 Million Cancer Deal With CRT Pioneer Fund 9/27/2016 6:43:43 AM
ProNAi Therapeutics Shuts Down Research Site for Failed Cancer Candidate PNT2258 8/12/2016 9:59:05 AM
ProNAi Therapeutics, Inc. Reports Interim Data From Wolverine Phase 2 Trial Of PNT2258 In DLBCL 6/6/2016 11:20:05 AM
ProNAi Therapeutics, Inc. Appoints Dr. Christian Hassig As Senior Vice President Of Research 6/1/2016 7:43:13 AM
ProNAi Therapeutics, Inc. To Report Wolverine Phase 2 Interim Results On June 6th At ASCO 5/19/2016 7:41:11 AM
ProNAi Therapeutics, Inc. Reports First Quarter 2016 Results 5/10/2016 8:22:28 AM
ProNAi Therapeutics, Inc. Appoints Jeffrey H. Cooper And Tran Nguyen To Its Board Of Directors 3/18/2016 6:28:07 AM
ProNAi Therapeutics, Inc. Granted Orphan Drug Designation For PNT2258 For The Treatment Of Diffuse Large B-Cell Lymphoma 3/14/2016 5:57:10 AM